Claims Study Shows Better Glycemic Control, Less Switching With Canagliflozin Than Dapagliflozin | RSS News Feed

Claims Study Shows Better Glycemic Control, Less Switching With Canagliflozin Than Dapagliflozin - Latest News

RSS Feed for this news: Claims Study Shows Better Glycemic Control, Less Switching With Canagliflozin Than Dapagliflozin

Real-World Study Shows INVOKANA® (canagliflozin) 300mg Demonstra - KPTV - FOX 12

First Real-World Study ... goal of less than 7.0 percent (36.7 vs. 25.1 percent, p<0.0001). Study and Findings The analysis was based on Optum Clinformatics™ claims data and looked at 558 INVOKANA ® patients and an equal number of matched dapagliflozin ... read more

Real-World Study Shows INVOKANA® (canagliflozin) 300mg Demonstra - wistv.com - Columbia, South Carolina

First Real-World Study ... goal of less than 7.0 percent (36.7 vs. 25.1 percent, p<0.0001). Study and Findings The analysis was based on Optum Clinformatics™ claims data and looked at 558 INVOKANA ® patients and an equal number of matched dapagliflozin ... read more

Real-World Study Shows INVOKANA® (canagliflozin) 300mg Demonstra - KLTV.com - Tyler, Longview, Jacksonville |ETX News

First Real-World Study ... goal of less than 7.0 percent (36.7 vs. 25.1 percent, p<0.0001). Study and Findings The analysis was based on Optum Clinformatics™ claims data and looked at 558 INVOKANA ® patients and an equal number of matched dapagliflozin ... read more

Looking for another news?


JOHNSON & JOHNSON : Janssen Presents New Data Showing INVOKANA® (canagliflozin) ..

78.3 percent (p=0.017) Blood pressure less than 130/80 mmHg: 54.2 percent vs. 32.5 percent (p=0.001) In the study ... World (RW) Glycemic Control and Medication Adherence among Patients with Type 2 Diabetes Mellitus (T2DM) Initiated on Canagliflozin ... read more

including the Annual Financial Report

has been filed with the French Autorité des marchés financiers (the “AMF”) on 26 April 2018 under number R.18- 031. This document cannot be used in connection with a financial transaction unless accompanied by a transaction note (note d’opération ... read more

THE CLINICAL ADVISOR • OCTOBER 2016

Editor Colby Stong, editor@ClinicalAdvisor.com Senior editor Sandhya George Associate editor Lauren Grygotis Assistant editor Madeline Morr Contributing editors Mark P. Brady, PA-C; Philip R. Cohen, MD; Deborah L. Cross, MPH, CRNP, ANP; Sharon Dudley-Brown ... read more


FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us